Trial of Efficacy of the RetroPerc Device
RetroPerc®-A Prospective, Multi-institutional Trial of Efficacy of the RetroPerc Device
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Nadeem N Dhanani, MD,MPH
- Phone Number: (713) 500-7337
- Email: Nadeem.N.Dhanani@uth.tmc.edu
Study Contact Backup
- Name: Amy Isidahomen
- Phone Number: 713-500-6086
- Email: Amy.Isidahomen@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Health Science Center at Houston
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
-Renal pelvis and proximal ureteral stones >10 mm confirmed with non-contrast computed tomography
Exclusion Criteria:
- Suspected pyelonephritis.
- Prior percutaneous nephrolithotomy procedure in affected kidney.
- Mid-ureteral or distal ureteral stones.
- Pregnancy.
Anatomical abnormal kidney, including:
- Horseshoe
- Ectopic
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment (retrograde nephrostomy)
|
this will consist of one visit to a urologist for retrograde nephrostomy placement using a Retroperc device with lithotomy performed in the same visit and follow up at 4 weeks and 6 months.
|
|
Active Comparator: Control Group ( antegrade nephrostomy)
|
this will consist of two visits, first to the interventional radiologist for antegrade nephrostomy placement followed by another visit to the urologist for lithotomy with follow up at 4 weeks and 6 months
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment efficacy as measured by the time taken from diagnosis to nephrostomy access
Time Frame: end of procedure (about 4-8 weeks from diagnosis)
|
end of procedure (about 4-8 weeks from diagnosis)
|
|
|
Treatment efficacy as measured by total time of access operation.
Time Frame: end of procedure( about 90 minutes after start of procedure)
|
end of procedure( about 90 minutes after start of procedure)
|
|
|
Treatment efficacy as measured by total time of access operation fluoroscopy
Time Frame: end of procedure( about 90 minutes after start of procedure)
|
end of procedure( about 90 minutes after start of procedure)
|
|
|
Treatment efficacy as measured by total time of lithotomy operation
Time Frame: end of procedure(about 3 hours after start of procedure)
|
end of procedure(about 3 hours after start of procedure)
|
|
|
Treatment efficacy as measured by total time of lithotomy operation fluoroscopy
Time Frame: (end of procedure)about 3 hours after start of procedure
|
(end of procedure)about 3 hours after start of procedure
|
|
|
Treatment efficacy as measured by length of post-operative hospital stay
Time Frame: 24 hours after procedure
|
24 hours after procedure
|
|
|
Number of patients that are stone free
Time Frame: 6-12 weeks after procedure
|
stone free is defined as <2mm on non-contrast computed tomography
|
6-12 weeks after procedure
|
|
Number of patients with symptom free survival as defined as lack of flank pain
Time Frame: 6-12 weeks after procedure
|
6-12 weeks after procedure
|
|
|
Number of patients with symptom free survival as defined as lack of presence of urinary or gastrointestinal symptoms,
Time Frame: 6-12 weeks after procedure
|
6-12 weeks after procedure
|
|
|
Number of patients with symptom free survival as defined as lack of limitations to work
Time Frame: 6-12 weeks after procedure
|
6-12 weeks after procedure
|
|
|
Number of patients with symptom free survival as defined as lack of limitations to social or daily activities.
Time Frame: 6-12 weeks after procedure
|
6-12 weeks after procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with nephrostomy access adequate for stone treatment
Time Frame: end of procedure( abut 3 hours from start of procedure)
|
end of procedure( abut 3 hours from start of procedure)
|
|
|
Number of patients with normal vital signs
Time Frame: end of procedure( abut 3 hours from start of procedure)
|
end of procedure( abut 3 hours from start of procedure)
|
|
|
Number of patients with normal laboratory values
Time Frame: 24 hours after procedure
|
laboratory values include complete metabolic panel and urinalysis
|
24 hours after procedure
|
|
Number of patients with an infection rate which is defined as a positive culture within the study time period
Time Frame: 6-12 weeks after procedure
|
6-12 weeks after procedure
|
|
|
Number of patients that require pain medication (defined as discharge with an opioid prescription).
Time Frame: 6-12 weeks after procedure
|
6-12 weeks after procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Nadeem N Dhanani, MD,MPH, The University of Texas Health Science Center, Houston
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Male Urogenital Diseases
- Calculi
- Pathological Conditions, Anatomical
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urolithiasis
- Urinary Calculi
- Nephrolithiasis
- Pathological Conditions, Signs and Symptoms
- Kidney Calculi
Other Study ID Numbers
Other Study ID Numbers
- HSC-MS-20-1269
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.